Zymeworks Inc (Zymeworks) is a clinical-stage biotechnology company that develops novel and multifunctional biotherapeutics. It utilizes Azymetric, Zymelink, EFECT, Protect and T Cell Engagers technology platforms to develop drugs. The company’s pipeline products include zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2) that treats gastroesophageal adenocarcinomas, biliary tract, gastrointestinal and breast cancer; and zanidatamab zovodotin is a HER2-targeted bispecific antibody-drug conjugate (ADC) for expressing cancers. Its preclinical products include ZW191, ZW171, ZW251 and ZW220 targeting ovarian, endometrial and lung and liver cancers and hepatocellular carcinoma, among others. The company operates through its subsidiaries in the US, Ireland, Canada, the UK and Singapore. Zymeworks is headquartered in Vancouver, British Columbia, Canada.
Headquarters
Canada
Address
Suite 800, 114 East 4th Avenue, Vancouver, British Columbia, V5T1G4
Website
www.zymeworks.com
Telephone
1 604 6781388
No of Employees
272
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
ZYME (NASD)
Revenue (2022)
$76.0M
-81.6%
(2022 vs 2021)
EPS
XYZ
Net Income (2022)
XYZ
-195.4%
(2022 vs 2021)
Market Cap*
$572.3M
Net Profit Margin (2022)
XYZ
-618.0%
(2022 vs 2021)
* As of and is in US$
Zymeworks Inc premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Pipeline | Zymeworks |
| Zanidatamab: | ProTECT |
| Biliary Tract Cancers | EFECT |
| XYZ | |
| XYZ | |
| XYZ |
Competitor Comparison
| Key Parameters | Zymeworks Inc | F. Hoffmann-La Roche Ltd | AstraZeneca Plc | Daiichi Sankyo Co Ltd | Jiangsu Hengrui Medicine Co Ltd |
|---|---|---|---|---|---|
| Headquarters | Canada | Switzerland | United Kingdom | Japan | China |
| City | Vancouver | Basel | Cambridge | Chuo-Ku | Lianyungang |
| State/Province | British Columbia | - | England | Tokyo | Jiangsu |
| No. of Employees | 272 | 103,605 | 89,900 | 17,435 | 19,611 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Kenneth Galbraith | Chairman; Chief Financial Officer - Interim; Chief Executive Officer | Executive Board | 2022 | 61 |
| Jeffrey Smith, M.D. | Executive Vice President; Chief Medical Officer | Senior Management | 2024 | 64 |
| Paul A. Moore, Ph.D. | Chief Scientific Officer | Senior Management | 2022 | 57 |
| John Fann, Ph.D. | Senior Vice President - Process Sciences | Senior Management | 2024 | - |
| Daniel Dex | Senior Vice President; General Counsel; Secretary | Senior Management | 2023 | - |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer